HSK31858, tablet

DRUG4 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

HealthyHealthy VolunteersNon-cystic Fibrosis Bronchiectasis

Phase 1

A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers

CompletedNCT05023525

Haisco Pharmaceutical Group Co., Ltd.Healthy

Start: 2021-10-28End: 2022-08-16Updated: 2022-09-06

Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers

CompletedNCT05663593

Haisco Pharmaceutical Group Co., Ltd.Healthy Volunteers

Start: 2022-02-23End: 2022-11-30Updated: 2022-12-23

Phase 3

A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

RecruitingNCT06660992

Haisco Pharmaceutical Group Co., Ltd.Non-cystic Fibrosis Bronchiectasis

Start: 2024-09-30End: 2027-01-27Target: 669Updated: 2024-10-28

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

RecruitingNCT07616375

Haisco Pharmaceutical Group Co., Ltd.Non-cystic Fibrosis Bronchiectasis

Start: 2025-09-28End: 2029-04-03Target: 669Updated: 2026-06-01

Related Papers

Florensocatib in adults with bronchiectasis: The HOPE-BE trial protocol and baseline demographic characteristics

ERJ Open Research2026-04-09

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology2025-04-024 citations